



ANNA L. COCUZZO

Page 1 of 2

MAR 24 2005

P CT  
21051YP

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/507,237	FIRST NAMED APPLICANT Emilio A. Emini	ATTY. DOCKET NO. 21051YP
---	--	-----------------------------

INTERNATIONAL APPLICATION NO. PCT/US03/07727
---

I.A. FILING DATE 03/12/2003	PRIORITY DATE 03/13/2002
--------------------------------	-----------------------------

000210  
MERCK AND CO., INC  
P O BOX 2000  
RAHWAY, NJ 07065-0907

MAR 24 2005

CONFIRMATION NO. 2340  
371 FORMALITIES LETTER  
\*OC000000015482149\*  
\*OC000000015482149\*

Date Mailed: 03/17/2005

*Sequence  
Due By*

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

*5-17-05*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
  - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c) and PCT Rule 5.2(a).
  - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of Annex C of the Administrative Instructions and 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
  - APPLICANT MUST PROVIDE:
    - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice MUST be returned with the response.*

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

KAREN R MCLEAN

By Merck & Co., Inc. Date April 24, 2005

Telephone: (703) 308-9140 EXT 214

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/507,237	PCT/US03/07727	21051YP

FORM PCT/DO/EO/922 (371 Formalities Notice)



JCO7 Rec'd PCT/PTO 25 APR 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By

Date

April 21, 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Emini, Emilio A. *et al.*

Serial No.: 10/507,237

Case No.: 21051YP

Art Unit:

Filed: September 9, 2004

Examiner:

For: METHOD OF INDUCING AN ENHANCED  
IMMUNE RESPONSE AGAINST HIV

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING AND AMENDMENT

Sir:

In response to the Notification to Comply with Requirements for Patent Applications containing Nucleotide and/or Amino Acid Sequence Disclosures mailed on March 17, 2005, enclosed herewith please find a Substitute Sequence Listing in paper and computer readable form. The paper and computer readable forms of the attached Substitute Sequence Listing are the same and do not contain new matter.

The Substitute Sequence Listing provides an identifier (<220> to <223>) for the "n" found within SEQ ID NO: 5 at position 34984. Said "n" was inadvertently not associated with an appropriate identifier (<220> to <223>) for sequence listings possessing an "n". Other than the addition of the typical "n" descriptor (n=a, t, c or g) and the inclusion of relevant filing information (*i.e.*, serial number and filing date of the current application), the Substitute Sequence Listing is identical to the previously submitted Sequence Listing.

Applicants respectfully request that said Substitute Sequence Listing be inserted into the application file in place of the Sequence Listing of record previously submitted on September 9, 2004.

No fee is believed to be due. The Commissioner is, however, authorized to charge Deposit Account No. 13-2755 for any amount deemed necessary to enter the enclosed Substitute Sequence Listing into the application file.

Respectfully submitted,

By 

Anna L. Cocuzzo  
Reg. No. 42,452  
Attorney for Applicants

Merck & Co., Inc.  
P.O. Box 2000  
Rahway, NJ 07065-0907  
(732) 594-1273

Date: April 21, 2005